Historical lly News Stories
Eli Lilly Q1 Beat Sparks Rally; Analysts Weigh In!
Eli Lilly reported a blockbuster Q1 with revenue up 56% and raised full-year guidance, fueled by rapid growth in GLP-1 franchises. A recent hepatic safety report briefly spurred volatility, but analysts largely view it as non-material while management deploys cash into strategic biotech acquisitions.
Foundayo Stumbles: Lilly Shares Slip, Insiders Buy
Eli Lilly's newly launched oral GLP‑1, Foundayo, recorded a weak second-week pickup that pressured LLY shares despite steady overall GLP‑1 script growth. Prescription data, a modest stock decline, and small insider purchases define the latest investor landscape and point to key near-term indicators to watch.
LLY Jumps: Foundayo Approval, Centessa Deal Lift+AI
Eli Lilly (LLY) saw fresh upside after FDA approval of oral GLP‑1 Foundayo and a major Centessa acquisition, while strategic gene‑editing and AI partnerships reshaped near‑term catalysts ahead of Q1 results.
Orforglipron Lift Pushes LLY Past $1,000 Milestone
Eli Lilly’s oral obesity drug Orforglipron (foundayo) delivered standout ATTAIN‑1 results and sparked strategic distribution deals with Weight Watchers and Amazon Pharmacy, driving LLY shares above $1,000. Concurrent data on lebrikizumab highlighted pipeline depth but investor focus remains on the obesity franchise and near‑term commercialization.
Lilly Foundayo Ignites Obesity Sales; Centessa LLY
Eli Lilly's FDA approval and launch of oral GLP‑1 pill Foundayo, plus a proposed acquisition of Centessa Pharmaceuticals, are near-term catalysts for LLY. Foundayo’s competitive pricing and rapid rollout, together with the Centessa deal, reshape Lilly’s growth trajectory and pipeline diversification.
Lilly Faces Drug Rivalry, China Push, Legal Risk!!
Eli Lilly shares slipped after analyst downgrades amid intensifying competition in oral obesity drugs, even as the company reported strong pipeline readouts and unveiled a $3 billion China expansion. Immediate catalysts include an imminent FDA decision on orforglipron and upcoming clinical readouts for retatrutide.
LillyPod Boosts Eli Lilly; JPMorgan Ups Stake Now!
Eli Lilly’s launch of LillyPod — a massive NVIDIA-powered AI supercomputing cluster — and JPMorgan’s recent 26% stake increase are reshaping investor expectations for LLY. Combined with Zepbound’s clinical edge in weight-loss data versus a rival GLP-1, these concrete developments strengthen Lilly’s R&D productivity outlook and institutional backing, with potential implications for revenue growth and stock sentiment.
LLY Surge: Orna Deal, Orforglipron FDA Moment Now!
Eli Lilly (LLY) saw fresh tailwinds this week as the company expanded into in vivo CAR‑T via the Orna Therapeutics acquisition, navigated acquisition chatter around Ventyx, and approaches a critical FDA decision for oral orforglipron. Early prescription data for Novo’s oral Wegovy and renewed technical momentum in LLY shares frame near‑term upside and volatility for investors.
Lilly Rises as Novo Trial Fails, GLP-1 Lead Widens
Eli Lilly gained market momentum after Novo Nordisk’s late‑stage CagriSema failure, reinforcing Lilly’s leadership in GLP‑1 obesity treatments. Combined with Lilly’s confidence in an oral GLP‑1 pill, a $3.5 billion Pennsylvania manufacturing investment, and analyst EPS upgrades, these concrete developments are reshaping near‑term growth expectations while regulatory pricing pressures remain a key risk.
Lilly: Price Caps Cut Obesity Margins; FDA NearFeb
In the past week Eli Lilly has faced a concrete policy and regulatory crossroads: new U.S. price caps and Medicare coverage for obesity drugs compress margins, while an FDA decision on Lilly’s oral GLP-1 candidate orforglipron is imminent. Meanwhile, a potential €15 billion Abivax acquisition and ongoing M&A moves illustrate management’s push to diversify beyond weight-loss franchises.
Lilly Surge: $3.5B Plant & Record 2026 Outlook Now
Eli Lilly (LLY) gained momentum this week after announcing a $3.5B Lehigh Valley manufacturing complex, issuing a bullish $80–$83B 2026 revenue guide driven by tirzepatide sales, and benefiting from regulatory moves that reduced low-cost competition. These concrete developments underpin near-term growth and investor confidence in LLY within the S&P 500.
Lilly Acquires Orna; GLP-1 Sales Drive Q4 Jump Now
Eli Lilly’s $2.4B buy of Orna Therapeutics and a blockbuster GLP‑1 quarter — driven by Mounjaro and Zepbound — underscore the company’s shift into cell and genetic therapies while sustaining outsized revenue growth. Strong Q4 results, bullish 2026 guidance, and an advancing oral GLP‑1 program combine with industry price competition to shape LLY’s near-term outlook.